Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2025-06-23 Proxy Solicitation & In…
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly mentions 'ANNUAL MEETING OF SHAREHOLDERS - PROXY' in the title and body. It is filed under 'Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation)' and attaches a file named '*FORM_DEF_14A_isa.pdf*'. The presence of 'PROXY' and the reference to 'FORM_DEF_14A' strongly indicates materials related to soliciting shareholder votes for a meeting. This aligns directly with the definition for Proxy Solicitation & Information Statement (PSI). Although DEF 14A is mentioned in the filename, the overall context of soliciting votes for the AGM points more specifically to PSI, which covers proxy materials. Given the explicit mention of 'PROXY' and the context of an 'ANNUAL MEETING OF SHAREHOLDERS', PSI is the most accurate classification for the solicitation material.
2025-06-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a detailed disclosure about a clinical study update and a press release related to the company's product OpRegen. It explicitly states that the information is being furnished and not filed for purposes of Section 18 of the Exchange Act, indicating it is a current event disclosure rather than a full financial report. There are no comprehensive financial statements or detailed financial analysis present, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing reporting a material event, which fits the category of Regulatory Filings (RNS). The document length is over 10,000 characters, so it is not a brief announcement. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2025-06-23 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a supplement to a proxy statement for the 2025 Annual Meeting of Shareholders, specifically updating shareholders about the change in the independent registered public accounting firm from Moss Adams LLP to Baker Tilly US, LLP. It references the original proxy statement and an 8-K filing but primarily serves as additional material related to the proxy solicitation for the annual meeting. The document is titled as a supplement to the proxy statement and is filed under Schedule 14A, which is used for proxy statements and related materials. It does not contain the full proxy statement itself but additional information to be considered alongside it. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI), as it is supplementary material provided to shareholders to inform and solicit votes for the annual meeting.
2025-06-11 English
8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 3, 2025, reporting a change in the company's independent registered public accounting firm due to a merger between Moss Adams LLP and Baker Tilly US, LLP. It details the resignation of Moss Adams and appointment of Baker Tilly as the new auditor. The document includes no financial statements or substantive financial data but focuses on auditor change disclosure and related certifications. This type of filing is a regulatory announcement about auditor changes, which fits the category of Audit Report / Information (AR) as it relates to audit firm changes and audit-related disclosures but is not a full annual report or audit report itself. The document is not a full Annual Report (10-K), nor is it a simple announcement of a report publication (RPA). Therefore, the best classification is AR with high confidence.
2025-06-09 English
First Quarter 2025 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document is titled "Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update." It explicitly details financial figures for the three months ended March 31, 2025, including Revenues, Operating Expenses (R&D and G&A), Loss from Operations, and Net Loss per share. This structure is characteristic of a periodic financial results announcement, specifically for a quarter. Since it provides the initial summary of quarterly results rather than a comprehensive, detailed filing like a 10-Q (which is not an option here), the most appropriate classification is Earnings Release (ER). It is not a full Annual Report (10-K), nor is it a transcript (CT) or a general investor presentation (IP). Q1 2025
2025-05-14 English
First Quarter 2025 Financial Results and Provides Business Update
Report Publication Announcement Classification · 99% confidence The document text explicitly states, "Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" and includes an attachment reference: "*First_Quarter_2025_Financial_Results_isa.pdf*". It is filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE) on 14/05/2025, reporting on the 'First Quarter 2025'. This indicates a comprehensive report for a period shorter than a year, which aligns with the definition of an Interim/Quarterly Report (IR). However, the document itself is very short (2027 chars) and primarily serves as an announcement stating that the results report is attached ('Attached hereto is a report on...'). According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report should be classified as a Report Publication Announcement (RPA). Since this document announces the release of the 'First Quarter 2025 Financial Results', RPA is the most appropriate classification based on the document's structure and length, even though the content relates to an Interim Report (IR).
2025-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.